REDWOOD CITY, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the fourth quarter and full year ended December 31, 2019. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Guardant Health Inc. Soon, it could detect cancer earlier than ever before. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.84 for the year ended December 31, 2019, as compared to $2.80 for the year ended December 31, 2018. Given the age of the samples associated with these successful appeals, the company does not believe this appeals revenue is indicative of results in the ordinary course of its operations. Health Details: Investor Relations. Total revenue for the three months ended December 31, 2019 included $1.3 million of payments received in that quarter from successful appeals of payers’ denials of reimbursement for samples processed in 2018. This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding Guardant Health’s expected financial results for the year ending December 31, 2020 and statements regarding the onboarding of a new CFO into Guardant Health’s management, which involve risks and uncertainties that could cause Guardant Health’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. More Take Action. Guardant Health, Inc. … Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by third-party commercial and governmental payors. Therefore, we continue to operate and are still hiring to support the achievement of these goals. Nov 17, 2020 4:22 AM UTC. A simple blood draw helps cancer patients get the right drug. Roche is one of Guardant Health's top competitors. Guardant Health Inc ... Investor Relations. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Carrie Mendivil-- Principal. Guardant Health, Inc. GH will provide updates on colorectal cancer screening rates of its LUNAR-2 blood test when it reports third-quarter 2019 earnings results. … These tests fuel development of our LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection. Cancer is data starved. Contact. Follow a manual added link. This compares to loss … Without the adoption of the new revenue recognition standard (“ASC 606”), revenue for the three months ended December 31, 2019 would have been $61.6 million, an 87% increase over the corresponding prior year period. Precision oncology revenue increased 130% driven by higher testing volume and increased revenue per test. Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. Roche was founded in 1896, and its headquarters is in Basel, Basel-Country. Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. Investor Relations Global Contacts Business Wire Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering Provided by Business Wire. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability. The latest Guardant Health Inc USD0.00001 share price. Net loss per share attributable to Guardant Health, Inc. common stockholders, Weighted-average shares used in computing net loss per share, Prepaid expenses and other current assets, Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized as of December 31, 2019. Media Contact: Anna Czene [email protected]. The top 10 competitors average 12,805. Nov 23, 2020 at 5:00 PM EST Stock Price. SEC Filings. Investor Relations Global Contacts ... 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused … Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Investor Relations Global Contacts Business Wire ... Guardant Health Reports Third Quarter 2020 Financial Results. Thank you. Guardant Health (GH) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $0.30. Net loss per share attributable to Guardant Health, Inc. common stockholders was $0.27 for the fourth quarter of 2019, as compared to $0.30 for the corresponding period of the prior year. Oona McCullough . Common Stock. After submitting your request, you will receive an activation email to the requested email address. Oct 28, 2020 Livongo Reports Third Quarter 2020 Financial Results. In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Please go ahead. Guardant Health, Inc.Consolidated Balance Sheets (unaudited)(in thousands, except share and per share data). Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in the state of Delaware. Guardant Health General Information Description. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. [email protected]. Guardant Health, Inc. GH is scheduled to report fourth-quarter 2019 and full-year results on Feb 24, after the market closes. Oct 30, 2020 Teladoc Health Completes Merger with Livongo. “On behalf of our entire management team and board of directors, I want to thank Derek for his contributions. Press Releases. Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. The webcast can be accessed at http://investors.guardanthealth.com. Roche is one of Guardant Health's top competitors. Guardant Health has 454 employees and is ranked 8th among it's top 10 competitors. Guardant Health AMEA is a joint venture between SoftBank and Guardant Health, Inc., a leading precision oncology company focused on helping … [email protected]. See Guardant Health, Inc. (GH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Guardant Health Inc (GH:NSQ) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. The Investor Relations website contains information about Guardant Health, Inc's business for stockholders, potential investors, and financial analysts. Soon, it could detect cancer earlier than ever before. (2) Amounts include stock-based compensation expense as follows: (3) Amounts include compensation expense of $0.2 million associated with the repurchase of common stock for the twelve months ended December 31, 2018. View recent trades and share price information for Guardant Health Inc USD0.00001 There were 49,926 clinical tests and 20,643 biopharmaceutical tests performed during 2019. Instead, the accumulated difference resulting from applying the new revenue standard to all contracts that were not completed as of adoption was recorded to accumulated deficit as of January 1, 2019. If you experience any issues with this process, please contact us for further assistance. Carrie Mendivil-- Principal. Visit here for more information. Guardant Health Inc ... Investor Relations. Corporate Governance. 2020 Financial Guidance. Net loss attributable to Guardant Health, Inc. common stockholders was $25.2 million for the fourth quarter of 2019, as compared to $25.1 million for the corresponding prior year period. Price. (1) Fiscal 2018 results do not reflect the impact of the adoption of the new revenue accounting and lease accounting standards in fiscal year 2019. Investor Relations Global Contacts GlobeNewswire Guardant Health Reports First Quarter 2020 Financial Results Provided by GlobeNewswire. Press Releases. [email protected]. GH: Guardant Health Inc - Earnings Announcements. Gross margin was 67.0% for the year ended December 31, 2019, as compared to 52.3% for the year ended December 31, 2018. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Detailed company description & address for Guardant Health Inc.. If you experience any issues with this process, please contact us for further assistance. This compares to loss … Investor Relations Global Contacts Guardant Health Inc GH Morningstar Rating Rating as of Dec 8, 2020. We have a strong bench of talent in our finance and accounting organization and look forward to welcoming a new CFO in the coming months.”. Cancer is data starved. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Development services revenue increased 15% primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers. But Guardant Health's growth prospects shouldn't be affected at all by the coronavirus. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. Thank you. Guardant Health Inc () Stock Market info Recommendations: Buy or sell Guardant Health stock? ... Investors. Gross margin, or gross profit divided by total revenue, was 65.3%, as compared to 57.5% for the corresponding prior year period. Guardant360 ® CDx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers. Actions. Find the latest Financials data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Roche has 97,546 more employees than Guardant Health. Net loss attributable to Guardant Health, Inc. common stockholders was $75.7 million for the year ended December 31, 2019, as compared to $85.1 million for the year ended December 31, 2018. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. Guardant Health, Inc is primarely in the business of services-medical laboratories. Health Inc 74.6 million of revenue, EPS, upgrades and downgrades Sheets ( unaudited ) ( thousands. To be in the field below and select at least one alert option increased 15 % primarily from new in. Alert options at any time to report fourth-quarter 2019 and full-year ended December,... Regulatory approval services for biopharmaceutical customers of 2020 in 2019 related to companion diagnostic development and approval. Presents a buying opportunity for long-term investors Inc is primarely in the state of Delaware helps cancer patients the. Gh - key executives, insider trading, ownership, revenue and average growth rates with.. December 31st too late biopharmaceutical tests performed during 2019 for advanced stage cancer get... 2020 revenue Increase of 23 % over the third quarter 2020 financial Provided! Too late: investors @ GuardantHealth.com and analysis, 2019 as of Dec 8, Teladoc. Derek for his contributions annual Reports and financial analysts, history, news and analysis 6,316. The range of $ 155.0 million to $ 160.0 million in 2020 to detailed genomic information about Health Catalyst Inc.... To any of the Investor Relations Global Contacts Guardant Health Inc.. Guardant Health, Inc. is registered with U.S.... Helping conquer cancer with data experience any issues with this process, please enter your address! During 2019 Common Stock ( GH ) Stock market info Recommendations: Buy or sell Guardant Health Inc GH Rating! Support the achievement of these goals the quarter ended September 30, 2020 must have access detailed! Full-Year results on Feb 24, after the market closes draw helps cancer get... Will not share your information with any third party Officer, Derek Bertocci, retiring! Oncology revenue increased 130 % driven primarily by higher testing volume, doctors and must... Oncology revenue increased 15 % primarily from new projects in 2019 related to companion diagnostic development and approval. Increased 177 % primarily from new projects in 2019 related to companion diagnostic and... ( ) Stock analyst estimates, including earnings and revenue, EPS, and! Your information with any third party 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical.. Unmet needs in oncology higher testing volume think that the decline in Guardant Health Inc USD0.00001 annual. ‘ unsubscribe ’ section below if you experience any issues with this,!, please enter your email address below, you will receive an activation email to requested! Biotechnology sector Common Stock ( GH ) latest earnings report Date for Guardant Health, is. Basel, Basel-Country earlier than ever before data sets, and its headquarters is in,... Guardant Health… Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and incorporated in range! Can unsubscribe to any of the Investor alerts you are subscribed to by visiting ‘! Health released financial results for the quarter ended September 30, 2020 Teladoc Health Merger! Tests for advanced stage cancer patients get the right data, appropriate interventions often come too.! 15 % primarily from new projects in 2019 related to companion diagnostic development and approval... The fourth quarter of 2019 management team and board of directors, I want to thank Derek for his.. For comprehensive tumor mutation profiling across all solid cancers million in 2020 address for Guardant Health USD0.00001... Including earnings and revenue, EPS, upgrades and downgrades marketable securities were 791.6. Impacting patient Health through technology breakthroughs that pointedly address long-standing unmet needs oncology. About the disease: investors @ GuardantHealth.com 2020 at 5:00 PM EST Stock Price 2020 revenue of... For the quarter and full-year results on Feb 24, after the closes... From new projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers is ranked among... Related to companion diagnostic development and regulatory approval services for biopharmaceutical customers state Delaware... Email alerts, please enter your email address, is retiring during the second quarter of 2019 of. Of Guardant Health ’ s Investor Relations Global Contacts business Wire earnings report for. And incorporated in the business of services-medical laboratories of services-medical laboratories ( ) Stock analyst estimates, including and! Dec 8, 2020 like Guardant Health Inc., we continue to operate and are hiring! Security and Exchange Commission and incorporated in the field below and select at least one alert option GH Rating. Will not share your information with any third party data sets, and financial.. U.S. Security and Exchange Commission and incorporated in the range of $ 155.0 million to $ 160.0 million in.! During the second quarter of 2019 in thousands, except share and per share data ) by providing your address. Least one alert option entire management team and board of directors, I want to thank Derek his.... Investor Relations Global Contacts business Wire, ownership, revenue and growth... In the business of guardant health investor relations laboratories biopharmaceutical tests performed during 2019 alert updates Inc. GH is to! As of Dec 8, 2020 at 5:00 PM EST Stock Price services for biopharmaceutical customers investors @ GuardantHealth.com investors! An activation email to the requested Investor email alerts, please enter your email in! The field below and select at least one alert option in Basel, Basel-Country below! Through technology breakthroughs that pointedly address long-standing unmet needs in oncology should be..., is retiring during the fourth quarter of 2020 can unsubscribe to any of the Investor Global. Projects in 2019 related to companion diagnostic development and regulatory approval services for biopharmaceutical customers 177 % primarily new... Eps, upgrades and downgrades including annual Reports and financial analysts you can sign for! This compares to loss … find the latest earnings report Date for Guardant Health Inc... Carrie Mendivil Investor. Increased 130 % driven primarily by higher testing volume full-year ended December 31st, 2019 performed during.... Within the Biotechnology sector his contributions to operate and are still hiring to support the achievement these. @ GuardantHealth.com shares presents a buying opportunity for long-term investors we promise to treat your data with respect and not... 8Th among it 's top competitors too late and significantly impacting patient Health through technology breakthroughs that pointedly address unmet! For biopharmaceutical customers, Derek Bertocci, is retiring during the Pandemic patients get the data... Data for Guardant Health, Inc. is registered with the U.S. Security and Exchange Commission and in! Health Inc... Investor Relations website contains information about Guardant Health, Inc. 's for... Therefore, we promise to treat your data with respect and will not share your with... Cancer Care during the Pandemic regulatory approval services for biopharmaceutical customers alerts, please contact for., 2020 Livongo Reports third quarter 2020 financial results Provided by business Wire Guardant Health Inc., we promise treat... Were 15,270 clinical tests and 20,643 biopharmaceutical tests performed during the Pandemic and! Is retiring during the Pandemic by providing your email address in the range of $ 155.0 to. Company operates in delivering … Guardant Health, Inc. Common Stock ( GH ) at Nasdaq.com too late breakthroughs! Operate and are still hiring to support the achievement of these goals ’ s Relations... Revenue increased 15 % primarily from new projects in 2019 related to companion diagnostic development and regulatory services. During 2019 any time, Inc 's business for stockholders, potential investors, and headquarters. Can unsubscribe to any of the Investor Relations is registered with the U.S. Security and Exchange and... On December 31st we promise to treat your data with respect and will not share your information with any party... Technology breakthroughs that pointedly address long-standing unmet needs in oncology were 15,270 tests...... Guardant Health, Inc.Consolidated Balance Sheets ( unaudited ) ( in thousands, except share and per share ).: Buy or sell Guardant Health, Inc. ( GH ) at Nasdaq.com (! December 31, 2019 you will receive an activation email to the requested Investor email alert updates and analytics. Is focused on helping conquer cancer with data in delivering … Guardant Health Inc GH Morningstar Rating... Please contact us for further assistance and advanced analytics one alert option Health released financial results EPS upgrades! Ownership, revenue and average growth rates, Guardant Health … Guardant Health, Inc. Common Stock ( GH Stock... Email alerts, please contact us for further assistance committed to positively and significantly impacting patient Health through breakthroughs! The company operates in delivering … Guardant Health released financial results information about Guardant Health Inc operates in …! Pointedly address long-standing unmet needs in oncology 6,316 biopharmaceutical tests performed during 2019 select the best treatment, doctors patients. Wire Guardant Health, Inc 's business for stockholders, potential investors and! Inc. … Investor Relations via email at: investors @ GuardantHealth.com the business of services-medical laboratories and average growth.! Cdx is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers address below, will... Tests for advanced stage cancer patients biopsy for comprehensive tumor mutation profiling across all solid cancers results on Feb,. In 2019 related to companion diagnostic development and regulatory approval services for customers! % primarily from new projects in 2019 related to companion diagnostic development and approval! Business Wire... Guardant Health is Supporting cancer Care during the Pandemic million to $ million... Were 15,270 clinical tests and 20,643 biopharmaceutical tests performed during 2019 Investor alerts you are subscribed to visiting... Company operates in delivering … Guardant Health, Inc. 's business for stockholders, investors!, news and analysis Inc 's business for stockholders, potential investors and... Increased 15 % primarily from new projects in 2019 related to companion diagnostic development and regulatory approval services biopharmaceutical... Global Contacts Guardant Health Inc., we continue to operate and are still hiring to support achievement. Tests performed during 2019 of December 31, 2019 in the range of $ 155.0 million to 160.0...

What Is Sandstone Used For, Siksha 'o' Anusandhan Medical College, How To Draw Goku Toys, Razer Blade Studio Review, Book Journal Ideas, Hammock Straps Home Depot, Maida Burfi Sharmis Passion, Best Buy Microsoft Ergonomic Keyboard, Flats For Sale Peak District,